⌘K
t
| Date | 4 Jan 2022 |
| Time | 07:00:12 |
| Category | Capital structure |
| ID | 2505X |
Polarean Imaging Plc
("Polarean" or the "Company")
Total Voting Rights
Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 209,249,966 ordinary shares of £0.00037 each.
The total issued share capital of the Company consists of 209,249,966 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
|
Polarean Imaging plc |
www.polarean.com / www.polarean-ir.com |
|||
|
Richard Hullihen, Chief Executive Officer |
Via Walbrook PR |
|||
|
Jonathan Allis, Chairman |
|
|||
|
|
|
|||
|
Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) |
+44 (0)20 7710 7600 |
|||
|
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) |
|
|||
|
Nick Adams / Fred Walsh (Corporate Broking) |
|
|||
|
|
|
|||
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
|||
|
Paul McManus / Anna Dunphy |
Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001 |
|||
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation. 129Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised 129Xe used to evaluate pulmonary function and to visualise the lung using MRI. The Group received a complete response letter on 5 October 2021.
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual economic burden of pulmonary disease in the US is estimated to be over US $150 billion.